Yael Gothelf - Brainstorm Cell VP Affairs
| GHDN Stock | EUR 2.69 0.00 0.00% |
Insider
Yael Gothelf is VP Affairs of Brainstorm Cell Therapeutics
| Phone | 201 488 0460 |
| Web | https://www.brainstorm-cell.com |
Brainstorm Cell Management Efficiency
The company has return on total asset (ROA) of (0.6831) % which means that it has lost $0.6831 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.9343) %, meaning that it generated substantial loss on money invested by shareholders. Brainstorm Cell's management efficiency ratios could be used to measure how well Brainstorm Cell manages its routine affairs as well as how well it operates its assets and liabilities.Brainstorm Cell Therapeutics has accumulated 3.04 M in total debt with debt to equity ratio (D/E) of 934.0, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Brainstorm Cell Ther has a current ratio of 0.95, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Brainstorm Cell until it has trouble settling it off, either with new capital or with free cash flow. So, Brainstorm Cell's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Brainstorm Cell Ther sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Brainstorm to invest in growth at high rates of return. When we think about Brainstorm Cell's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Tomas Duffy | SIVERS SEMICONDUCTORS AB | 62 | |
| Sean Marett | BioNTech SE | 58 | |
| James Mock | Moderna | 46 | |
| Stephen Koch | Reliance Steel Aluminum | 56 | |
| Jeffrey Durham | Reliance Steel Aluminum | 60 | |
| Ingrid Engstrom | SIVERS SEMICONDUCTORS AB | 59 | |
| Lavina CFA | Moderna | N/A | |
| Robert Langer | Moderna | 73 | |
| Elizabeth Tallett | Moderna | 70 | |
| Robert Green | SIVERS SEMICONDUCTORS AB | 60 | |
| Arvid Moss | Norsk Hydro ASA | 65 | |
| Paul Sagan | Moderna | 59 | |
| Noubar Afeyan | Moderna | 60 | |
| Marcello Damiani | Moderna | 49 | |
| Erik Wiklund | SIVERS SEMICONDUCTORS AB | 49 | |
| Vandy Lupton | Reliance Steel Aluminum | N/A | |
| Sierk Poetting | BioNTech SE | 50 | |
| Harry Kanwar | Superior Plus Corp | N/A | |
| Arthur Ajemyan | Reliance Steel Aluminum | 47 | |
| Sean Mollins | Reliance Steel Aluminum | 44 | |
| AnneLene Midseim | Norsk Hydro ASA | 55 | |
Management Performance
| Return On Equity | -1.93 | |||
| Return On Asset | -0.68 |
Brainstorm Cell Ther Leadership Team
Elected by the shareholders, the Brainstorm Cell's board of directors comprises two types of representatives: Brainstorm Cell inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Brainstorm. The board's role is to monitor Brainstorm Cell's management team and ensure that shareholders' interests are well served. Brainstorm Cell's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Brainstorm Cell's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Yael Gothelf, VP Affairs | ||
| Irit DSc, CoFounder Board | ||
| Antal PearlLendner, VP Counsel | ||
| Daniel Offen, Chief Advisor | ||
| Stacy Lindborg, Exec Officer | ||
| Ralph Kern, COO and Chief Medical Officer | ||
| Chaim Lebovits, President CEO | ||
| PharmD MBA, Ex COO | ||
| Uri Yablonka, Executive Vice President Chief Business Officer, Director |
Brainstorm Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Brainstorm Cell a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.93 | |||
| Return On Asset | -0.68 | |||
| Current Valuation | 44.56 M | |||
| Shares Outstanding | 36.54 M | |||
| Shares Owned By Insiders | 22.70 % | |||
| Shares Owned By Institutions | 10.41 % | |||
| Price To Book | 36.30 X | |||
| EBITDA | (24.28 M) | |||
| Net Income | (24.46 M) | |||
| Cash And Equivalents | 6.22 M |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Brainstorm Stock
When determining whether Brainstorm Cell Ther offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Brainstorm Cell's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Brainstorm Cell Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Brainstorm Cell Therapeutics Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.